Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but….
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic pooling
PubMed 30032220 · doi:10.1093/advances/nmy010
What was done
This narrative review examined the biological mechanisms, clinical trial evidence, and clinical management strategies regarding the use of coenzyme Q10 (CoQ10) supplementation to treat statin-associated muscle symptoms (SAMS).
What was found
The abstract reports that estimated SAMS incidence ranges from less than 1% in industry-funded trials to 10% to 25% in non-industry-funded trials and approximately 60% in observational studies. While statin inhibition of the mevalonate pathway reduces CoQ10 synthesis, clinical trials evaluating CoQ10 supplementation to mitigate muscle symptoms have yielded equivocal and conflicting results. Specific numerical effect sizes or trial counts were not provided in the abstract.
Why it matters
CoQ10 is widely used by patients to prevent or alleviate statin intolerance, but current evidence does not consistently demonstrate clinical benefit.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The underlying trial evidence reviewed remains conflicting, and the abstract provides no specific patient numbers or outcome statistics.
Cited by
- supports The mevalonate/HMG-CoA pathway targeted by statins for cholesterol synthesis is also required for the endogenous synthesis of coenzyme Q10 (ubiquinol).